<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01931761</url>
  </required_header>
  <id_info>
    <org_study_id>D1532C00077</org_study_id>
    <nct_id>NCT01931761</nct_id>
  </id_info>
  <brief_title>Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in Volunteers</brief_title>
  <official_title>A Phase I, Single-centre, Non-randomised, Open-label, Pharmacokinetic and Mass Balance Study of Orally Administered [14C]-Selumetinib in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the absorption, distribution, metabolism and excretion (ADME) of single dose
      [14C] selumetinib in volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of total radioactivity in blood and plasma and percentage of radioactive dose in urine and faeces and total balance</measure>
    <time_frame>Samples collected prior to treatment, during treatment and follow-up for a maximum of 14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolite profiling and identification in plasma and excreta</measure>
    <time_frame>Samples collected prior to treatment, during treatment and follow-up for a maximum of 14 days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of selumetinib</measure>
    <time_frame>Samples collected prior to treatment, during treatment and follow-up for a maximum of 14 days.</time_frame>
    <description>Cmax, tmax, tÂ½, AUC, CL/F, Vz/F, MRT, fe, Ae, CLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of selumetinib</measure>
    <time_frame>Samples collected prior to treatment, during treatment and follow-up for a maximum of 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Assessments prior to treatment and after treatment including follow up.</time_frame>
    <description>Adverse events, vital signs, electrocardiogram, haematology, clinical chemistry, urinalysis, physical examination, left ventricular ejection fraction, and opthalmology assessments.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Solid Tumours</condition>
  <arm_group>
    <arm_group_label>[C14] selumetinib 75mg single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[C14] selumetinib 75mg single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[C14] selumetinib (oral)</intervention_name>
    <description>Single oral administration [C14] 75mg</description>
    <arm_group_label>[C14] selumetinib 75mg single dose</arm_group_label>
    <other_name>Selumetinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed and dated, written informed consent prior to any study specific
             procedures.

          -  Have a body mass index (BMI) between 18 and 32 kg/m2 inclusive and weigh at least 50
             kg and no more than 100 kg, inclusive.

          -  Regular bowel movements (ie, on average production of at least 1 stool per day).

        Exclusion Criteria:

          -  Current or past history of central serous retinopathy or retinal vein thrombosis,
             intraocular pressure greater than 21 mmHg or uncontrolled glaucoma.

          -  Exposure to radiation levels above background exceeding 5 mSv in the last 12 months or
             10 mSv in the last 5 years.

          -  History or presence of any clinically significant disease or disorder in the opinion
             of the investigator

          -  Any clinically important abnormalities in clinical chemistry, haematology, or
             urinalysis results, vital signs or ECG at baseline in the opinion of the Investigator.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart Mair, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Aberdeen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ruddington</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=1869&amp;filename=CSR_Synopsis_D1532C00077.pdf</url>
    <description>CSR_Synopsis_D1532C00077.pdf</description>
  </link>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2013</study_first_submitted>
  <study_first_submitted_qc>August 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2013</study_first_posted>
  <last_update_submitted>June 29, 2015</last_update_submitted>
  <last_update_submitted_qc>June 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics, mass balance, AZD6244</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

